metaMe Health, Inc., a Chicago, IL-based Prescription Digital Therapeutics (PDT) company, raised $2.2M in a bridge funding round.
The round was led by Hyde Park Angels (HPA), with participation from some individuals. With the funding, Ken Greisman, the deal lead from HPA and a veteran of the pharmaceutical industry, joined the metaMe board of directors.
The company intends to use the funds to continue preparation for Regulora’s market launch and to build out its commercial infrastructure.
Led by Tim Rudolphi, CEO, metaMe Health is advancing ReguloraⓇ, a FDA-authorized Prescription Digital Therapeutics (PDT specifically for abdominal pain associated with Irritable Bowel Syndrome (IBS) in adults. It provides relief to these patients through Gut-Directed Hypnotherapy (GDH) through a smartphone app. The app guides patients through seven treatment sessions and additional practice sessions over the course of three months, helping promote healthier control of digestive tract function and mitigate pain sensation. GDH has been shown to produce positive outcomes for those living with IBS, but has previously been inconvenient for many patients, as it has required in-person visits with licensed therapists. With Regulora, patients can access treatment privately from anywhere at any time, empowering them to improve their quality of life without hassle or fear of stigma.
FinSMEs
16/03/2022